Anti-tumor composition

Details Anti-tumor composition Anti-tumor composition

2005-08-04

2010-02-02

Kwon, Brian-Yong S (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heavy metal containing doai

C514S598000, C514S592000, C514S646000, C514S720000, C514S519000

Reexamination Certificate

active

07655696

ABSTRACT:
The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

REFERENCES:
patent: 4140707 (1979-02-01), Cleare et al.
patent: 4935450 (1990-06-01), Cone, Jr.
patent: 5525632 (1996-06-01), Obsumi et al.
patent: 5674906 (1997-10-01), Hatanaka et al.
patent: 5700826 (1997-12-01), Mjalli et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5731353 (1998-03-01), Ohsumi et al.
patent: 5844001 (1998-12-01), McClay et al.
patent: 6462087 (2002-10-01), Morinaga et al.
patent: 6933320 (2005-08-01), Bissery
patent: 6992106 (2006-01-01), Morinaga et al.
patent: 2002/0193434 (2002-12-01), Morinaga et al.
patent: 0 276 051 (1988-07-01), None
patent: 0 641 767 (1995-03-01), None
patent: 7-228558 (1995-08-01), None
patent: 8-301831 (1996-11-01), None
patent: WO 91/04058 (1991-04-01), None
patent: WO 92/16486 (1992-10-01), None
patent: WO 95/00129 (1995-01-01), None
patent: WO 95/20960 (1995-08-01), None
patent: WO 97/08184 (1997-03-01), None
patent: WO 98/33481 (1998-08-01), None
patent: WO 00/09097 (2000-02-01), None
patent: WO 00/48590 (2000-08-01), None
patent: WO 01/12579 (2001-02-01), None
patent: WO 02/056692 (2002-07-01), None
patent: WO 02/074229 (2002-09-01), None
Vippagunta (Adv. Drug Del. Rev., 2001, vol. 48, 2001, pp. 3-26).
“Enhancing and Inhibitory Effects of Some Stilbene and Steroid Compounds on Induction of Hepatoma in Rats Fed 3′Methyl-4-(Dimethylamino)Azobenzene”, Gann, 69, No. 3, pp. 375-382, Jun. 1978 (Chiba).
Anti-Leukaemic Compounds Derived From Stilbenes in Picea Abies Bark:, Phytochemistry, vol. 33, No. 4, 1993, pp. 813-816.
Tashiro, Nippon Kagaku Kaishi (1988), 684-90 Abstract Only.
American Association for Cancer Research, Eighty-Ninth Annual Meeting, Proceedings, Mar. 28-Apr. 1, 1998, New Orleans, LA., vol. 39—Mar. 1998.
B. Nakata, et al., Cancer Chemotherapy and Pharmacology, vol. 35, No. 6, pp. 511-518. XP-008010359, “Synergistic Interaction Between Cisplatin and Tamoxifen Delays the Emergence of Cisplatin Resistance in Head and Neck Cancer Cell Lines”, 1995.
E.F. McClay, et al., “British Journal of Cancer, vol. 70, No. 3, pp. 449-452, XP-008010360, 'Tamoxifen Delays the Development of Resistance to Cisplatin in Human Melanoma and Ovarian Cancer Cell Lines”, 1994.
Patent Abstracts of Japan, JP 56-103192, Aug. 18, 1981.
M. Cushman, et al., Journal of Medicinial Chemistry, vol. 34, No. 8, pp. 2579-2588, XP-000571676, “Synthesis and Evaluation of Stilbene and Dihydrostilbene Derivatives As Potential Anticancer Agents That Inhibit Tubulin Polymerization”, 1991.
J.A. Woods, et al., British Journal of Cancer, vol. 71, No. 4, pp. 705-711, XP-000978556, “The Interaction With Tubulin of a Series of Stilbenes Based on Combretastatin A-4”, 1995.

Affiliated with

Also associated with

Rating

Anti-tumor composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-tumor composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4230701